Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | RUVBL1 | Q9Y265 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8273828 | 0.82 | DPP4 (0.44) | PADI4ALDH1A1HSD17B10HPGDLMNA | |
| Hydrochloric Acid SCHEMBL4893749 | 0.81 | DPP4 (0.44) | PADI4ALDH1A1HSD17B10HPGDLMNA | |
| Hydrochloric Acid SCHEMBL27694404 | 0.81 | DPP4 (0.44) | PADI4ALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL14280849 | 0.80 | CTSS (0.40) | PADI4ALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL4890711 | 0.78 | KDM4E (0.41) | ALDH1A1HSD17B10HPGDLMNARAB9A | |
| SCHEMBL14315935 | 0.75 | ALDH1A1 (0.48) | PADI4ALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL4895208 | 0.71 | KDM4E (0.61) | PADI4ALDH1A1HSD17B10MAPK14KDM4E | |
| SCHEMBL4897701 | 0.66 | SCN9A (0.39) | — | |
| SCHEMBL4489140 | 0.65 | DPP4 (0.41) | — | |
| SCHEMBL4897316 | 0.65 | PYGL (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | PADI4 146/4885ALDH1A1 418/4885HSD17B10 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.